{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T14:22:36Z","timestamp":1788618156530,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T00:00:00Z","timestamp":1688947200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T00:00:00Z","timestamp":1688947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s40266-023-01048-y","type":"journal-article","created":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T18:02:42Z","timestamp":1689012162000},"page":"837-846","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Associated Factors to Efficacy and Tolerance of Immunotherapy in Older Patients with Cancer Aged 70 Years and Over: Impact of Coprescriptions"],"prefix":"10.1007","volume":"40","author":[{"given":"Marie","family":"Perret","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7934-9509","authenticated-orcid":false,"given":"Aur\u00e9lie","family":"Bertaut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3563-4658","authenticated-orcid":false,"given":"Julie","family":"Niogret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Marilier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Jouanny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5518-9803","authenticated-orcid":false,"given":"Patrick","family":"Manckoundia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0762-7303","authenticated-orcid":false,"given":"Le\u00efla","family":"Bengrine-Lefevre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Quipourt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7140-8415","authenticated-orcid":false,"given":"J\u00e9r\u00e9my","family":"Barben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,10]]},"reference":[{"key":"1048_CR1","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/ijc.31664","volume":"144","author":"S Pilleron","year":"2019","unstructured":"Pilleron S, Sarfati D, Janssen-Heijnen M, Vignat J, Ferlay J, Bray F, et al. Global cancer incidence in older adults, 2012 and 2035: a population-based study. Int J Cancer. 2019;144:49\u201358.","journal-title":"Int J Cancer"},{"key":"1048_CR2","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1093\/annonc\/mdz178","volume":"30","author":"G Carioli","year":"2019","unstructured":"Carioli G, Malvezzi M, Bertuccio P, Hashim D, Waxman S, Negri E, et al. Cancer mortality in the elderly in 11 countries worldwide, 1970\u20132015. Ann Oncol. 2019;30:1344\u201355.","journal-title":"Ann Oncol"},{"key":"1048_CR3","doi-asserted-by":"publisher","first-page":"738","DOI":"10.3390\/cancers12030738","volume":"12","author":"RK Vaddepally","year":"2020","unstructured":"Vaddepally RK, Kharel P, Pandey R, Garje R, Chandra AB. Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers. 2020;12:738.","journal-title":"Cancers"},{"key":"1048_CR4","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40425-018-0336-8","volume":"6","author":"R Elias","year":"2018","unstructured":"Elias R, Giobbie-Hurder A, McCleary NJ, Ott P, Hodi FS, Rahma O. Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis. J Immunother Cancer. 2018;6:26.","journal-title":"J Immunother Cancer"},{"issue":"12","key":"1048_CR5","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s40266-021-00899-7","volume":"38","author":"A Luciani","year":"2021","unstructured":"Luciani A, Ghidini A, Dottorini L, Petrelli F. Safety and effectiveness of immune checkpoint inhibitors in older patients with cancer: a systematic review of 48 real-world studies. Drugs Aging. 2021;38(12):1055\u201365.","journal-title":"Drugs Aging"},{"key":"1048_CR6","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s40266-020-00788-5","volume":"37","author":"T Landre","year":"2020","unstructured":"Landre T, Des Guetz G, Chouahnia K, Fossey-Diaz V, Culine S. Immune checkpoint inhibitors for patients aged \u2265 75 years with advanced cancer in first- and second-line settings: a meta-analysis. Drugs Aging. 2020;37:747\u201354.","journal-title":"Drugs Aging"},{"key":"1048_CR7","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.jgo.2021.02.002","volume":"12","author":"AC Johns","year":"2021","unstructured":"Johns AC, Wei L, Grogan M, Hoyd R, Bridges JFP, Patel SH, et al. Checkpoint inhibitor immunotherapy toxicity and overall survival among older adults with advanced cancer. J Geriatr Oncol. 2021;12:813\u20139.","journal-title":"J Geriatr Oncol"},{"key":"1048_CR8","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1001\/jamaoncol.2021.4960","volume":"7","author":"CA Nebhan","year":"2021","unstructured":"Nebhan CA, Cortellini A, Ma W, Ganta T, Song H, Ye F, et al. Clinical outcomes and toxic effects of single-agent immune checkpoint inhibitors among patients aged 80 years or older with cancer: a multicenter international cohort study. JAMA Oncol. 2021;7:1856\u201361.","journal-title":"JAMA Oncol"},{"key":"1048_CR9","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ejca.2020.01.013","volume":"129","author":"C Baldini","year":"2020","unstructured":"Baldini C, Martin Romano P, Voisin A-L, Danlos F-X, Champiat S, Laghouati S, et al. Impact of aging on immune-related adverse events generated by anti\u2013programmed death (ligand) PD-(L)1 therapies. Eur J Cancer. 2020;129:71\u20139.","journal-title":"Eur J Cancer"},{"key":"1048_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2020.100042","volume":"6","author":"F Gomes","year":"2021","unstructured":"Gomes F, Lorigan P, Woolley S, Foden P, Burns K, Yorke J, et al. A prospective cohort study on the safety of checkpoint inhibitors in older cancer patients - the ELDERS study. ESMO Open. 2021;6: 100042.","journal-title":"ESMO Open."},{"key":"1048_CR11","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.3461","volume":"5","author":"SJ Schonfeld","year":"2022","unstructured":"Schonfeld SJ, Tucker MA, Engels EA, Dores GM, Sampson JN, Shiels MS, et al. Immune-related adverse events after immune checkpoint inhibitors for melanoma among older adults. JAMA Netw Open. 2022;5: e223461.","journal-title":"JAMA Netw Open"},{"issue":"14","key":"1048_CR12","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1002\/cncr.34230","volume":"128","author":"CP Bruijnen","year":"2022","unstructured":"Bruijnen CP, Koldenhof JJ, Verheijden RJ, van den Bos F, Emmelot-Vonk MH, Witteveen PO, et al. Frailty and checkpoint inhibitor toxicity in older patients with melanoma. Cancer. 2022;128(14):2746\u201352.","journal-title":"Cancer"},{"key":"1048_CR13","unstructured":"U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health, National Cancer Institute. Common terminology criteria for adverse events (CTCAE) version 5.0. 2017. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf."},{"key":"1048_CR14","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1080\/0284186X.2019.1695062","volume":"59","author":"K Ninomiya","year":"2020","unstructured":"Ninomiya K, Oze I, Kato Y, Kubo T, Ichihara E, Rai K, et al. Influence of age on the efficacy of immune checkpoint inhibitors in advanced cancers: a systematic review and meta-analysis. Acta Oncol. 2020;59:249\u201356.","journal-title":"Acta Oncol"},{"key":"1048_CR15","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","volume":"389","author":"A Rittmeyer","year":"2017","unstructured":"Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389:255\u201365.","journal-title":"Lancet"},{"key":"1048_CR16","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A, et al. Pembrolizumab versus chemotherapy for PD-L1\u2013positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823\u201333.","journal-title":"N Engl J Med"},{"key":"1048_CR17","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711\u201323.","journal-title":"N Engl J Med"},{"key":"1048_CR18","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627\u201339.","journal-title":"N Engl J Med"},{"key":"1048_CR19","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.4049\/jimmunol.175.3.1483","volume":"175","author":"F Baratelli","year":"2005","unstructured":"Baratelli F, Lin Y, Zhu L, Yang S-C, Heuz\u00e9-Vourc\u2019h N, Zeng G, et al. Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells. J Immunol. 2005;175:1483\u201390.","journal-title":"J Immunol"},{"key":"1048_CR20","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.3389\/fimmu.2019.01832","volume":"10","author":"M Bassani-Sternberg","year":"2019","unstructured":"Bassani-Sternberg M, Digklia A, Huber F, Wagner D, Sempoux C, Stevenson BJ, et al. A phase Ib study of the combination of personalized autologous dendritic cell vaccine, aspirin, and standard of care adjuvant chemotherapy followed by nivolumab for resected pancreatic adenocarcinoma\u2014a proof of antigen discovery feasibility in three patients. Front Immunol. 2019;10:1832.","journal-title":"Front Immunol"},{"issue":"67","key":"1048_CR21","first-page":"674","volume":"2019","author":"By the 2019 American Geriatrics Society Beers Criteria\u00ae Update Expert Panel. American Geriatrics Society","year":"2019","unstructured":"By the 2019 American Geriatrics Society Beers Criteria\u00ae Update Expert Panel. American Geriatrics Society. Updated AGS Beers Criteria\u00ae for potentially inappropriate medication use in older adults: 2019 AGS BEERS CRITERIA\u00ae UPDATE EXPERT PANEL. J Am Geriatr Soc. 2019;2019(67):674\u201394.","journal-title":"J Am Geriatr Soc"},{"key":"1048_CR22","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.3748\/wjg.v25.i22.2706","volume":"25","author":"G Bruno","year":"2019","unstructured":"Bruno G, Zaccari P, Rocco G, Scalese G, Panetta C, Porowska B, et al. Proton pump inhibitors and dysbiosis: current knowledge and aspects to be clarified. WJG. 2019;25:2706\u201319.","journal-title":"WJG"},{"key":"1048_CR23","doi-asserted-by":"publisher","first-page":"1929727","DOI":"10.1080\/2162402X.2021.1929727","volume":"10","author":"B-D Qin","year":"2021","unstructured":"Qin B-D, Jiao X-D, Zhou X-C, Shi B, Wang J, Liu K, et al. Effects of concomitant proton pump inhibitor use on immune checkpoint inhibitor efficacy among patients with advanced cancer. Oncoimmunology. 2021;10:1929727.","journal-title":"Oncoimmunology."},{"key":"1048_CR24","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.21037\/atm-20-7498","volume":"8","author":"C Li","year":"2020","unstructured":"Li C, Xia Z, Li A, Meng J. The effect of proton pump inhibitor uses on outcomes for cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Ann Transl Med. 2020;8:1655\u20131655.","journal-title":"Ann Transl Med."},{"key":"1048_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106972","volume":"88","author":"M Li","year":"2020","unstructured":"Li M, Zeng C, Yao J, Ge Y, An G. The association between proton pump inhibitors use and clinical outcome of patients receiving immune checkpoint inhibitors therapy. Int Immunopharmacol. 2020;88: 106972.","journal-title":"Int Immunopharmacol"},{"key":"1048_CR26","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.annonc.2020.01.006","volume":"31","author":"M Chalabi","year":"2020","unstructured":"Chalabi M, Cardona A, Nagarkar DR, Dhawahir Scala A, Gandara DR, Rittmeyer A, et al. Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials. Ann Oncol. 2020;31:525\u201331.","journal-title":"Ann Oncol"},{"key":"1048_CR27","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.21873\/anticanres.15638","volume":"42","author":"I Tomisaki","year":"2022","unstructured":"Tomisaki I, Harada M, Minato A, Nagata Y, Kimuro R, Higashijima K, et al. Impact of the use of proton pump inhibitors on pembrolizumab effectiveness for advanced urothelial carcinoma. Anticancer Res. 2022;42:1629\u201334.","journal-title":"Anticancer Res"},{"key":"1048_CR28","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s40266-014-0166-4","volume":"31","author":"GMC Masclee","year":"2014","unstructured":"Masclee GMC, Sturkenboom MCJM, Kuipers EJ. A benefit-risk assessment of the use of proton pump inhibitors in the elderly. Drugs Aging. 2014;31:263\u201382.","journal-title":"Drugs Aging"},{"key":"1048_CR29","doi-asserted-by":"publisher","first-page":"4105","DOI":"10.1007\/s00520-018-4281-3","volume":"26","author":"A Whitman","year":"2018","unstructured":"Whitman A, DeGregory K, Morris A, Mohile S, Ramsdale E. Pharmacist-led medication assessment and deprescribing intervention for older adults with cancer and polypharmacy: a pilot study. Support Care Cancer. 2018;26:4105\u201313.","journal-title":"Support Care Cancer"},{"key":"1048_CR30","doi-asserted-by":"publisher","first-page":"5797","DOI":"10.1073\/pnas.1219686110","volume":"110","author":"A Steptoe","year":"2013","unstructured":"Steptoe A, Shankar A, Demakakos P, Wardle J. Social isolation, loneliness, and all-cause mortality in older men and women. Proc Natl Acad Sci USA. 2013;110:5797\u2013801.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1048_CR31","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1093\/ageing\/afaa177","volume":"50","author":"MV Vyas","year":"2021","unstructured":"Vyas MV, Watt JA, Yu AYX, Straus SE, Kapral MK. The association between loneliness and medication use in older adults. Age Ageing. 2021;50:587\u201391.","journal-title":"Age Ageing"},{"key":"1048_CR32","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1001\/jamainternmed.2021.3775","volume":"181","author":"AA Kotwal","year":"2021","unstructured":"Kotwal AA, Steinman MA, Cenzer I, Smith AK. Use of high-risk medications among lonely older adults: results from a nationally representative sample. JAMA Intern Med. 2021;181:1528\u201330.","journal-title":"JAMA Intern Med"},{"key":"1048_CR33","doi-asserted-by":"publisher","first-page":"15793","DOI":"10.3390\/ijerph192315793","volume":"19","author":"J Pola\u0144ski","year":"2022","unstructured":"Pola\u0144ski J, Misi\u0105g W, Chabowski M. Impact of loneliness on functioning in lung cancer patients. Int J Environ Res Public Health. 2022;19:15793.","journal-title":"Int J Environ Res Public Health"},{"key":"1048_CR34","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.jgo.2016.05.007","volume":"7","author":"C Helissey","year":"2016","unstructured":"Helissey C, Vicier C, Champiat S. The development of immunotherapy in older adults: new treatments, new toxicities? J Geriatr Oncol. 2016;7:325\u201333.","journal-title":"J Geriatr Oncol."},{"key":"1048_CR35","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s12094-019-02167-y","volume":"22","author":"J Feliu","year":"2020","unstructured":"Feliu J, Heredia-Soto V, Giron\u00e9s R, Jim\u00e9nez-Munarriz B, Salda\u00f1a J, Guill\u00e9n-Ponce C, et al. Management of the toxicity of chemotherapy and targeted therapies in elderly cancer patients. Clin Transl Oncol. 2020;22:457\u201367.","journal-title":"Clin Transl Oncol"},{"key":"1048_CR36","doi-asserted-by":"publisher","first-page":"2808","DOI":"10.1093\/annonc\/mdt360","volume":"24","author":"C Falandry","year":"2013","unstructured":"Falandry C, Weber B, Savoye A-M, Tinquaut F, Tredan O, Sevin E, et al. Development of a geriatric vulnerability score in elderly patients with advanced ovarian cancer treated with first-line carboplatin: a GINECO prospective trial. Ann Oncol. 2013;24:2808\u201313.","journal-title":"Ann Oncol"}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-023-01048-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-023-01048-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-023-01048-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T07:22:00Z","timestamp":1692861720000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-023-01048-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,10]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["1048"],"URL":"https:\/\/doi.org\/10.1007\/s40266-023-01048-y","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,10]]},"assertion":[{"value":"19 June 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research received no external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Marie Perret, Aur\u00e9lie Bertaut, Julie Niogret, Sophie Marilier, Pierre Jouanny, Patrick Manckoundia, Le\u00efla Bengrine-Lefevre, Val\u00e9rie Quipourt, and J\u00e9r\u00e9my Barben declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"Ethical approval was waived by the local Ethics Committee of University of Burgundy in view of the retrospective nature of the study and since all the procedures performed were part of the routine care.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Conceptualization: J\u00e9r\u00e9my Barben and Aur\u00e9lie Bertaut; methodology: Aur\u00e9lie Bertaut; software: Aur\u00e9lie Bertaut; validation: Val\u00e9rie Quipourt, Leila Bengrine-Lefevre, Julie Niogret, Pierre Jouanny, Sophie Marilier, and Patrick Manckoundia; formal analysis: Aur\u00e9lie Bertaut; data curation: Marie Perret; writing\u2014original draft preparation: Marie Perret and J\u00e9r\u00e9my Barben; writing\u2014review and editing: Val\u00e9rie Quipourt, Leila Bengrine-Lefevre, Julie Niogret, Pierre Jouanny, Sophie Marilier, and Patrick Manckoundia; supervision: J\u00e9r\u00e9my Barben.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"The datasets generated during and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}}]}}